Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.
The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.
TransCode Therapeutics (NASDAQ:RNAZ) today announced positive preclinical data demonstrating that its lead candidate, TTX-MC138, successfully reaches orthotopic glioblastoma tumors following intravenous administration and achieves sustained target engagement against miR-10b.
Lockheed Martin (NYSE:LMT) announced a transformative seven-year framework agreement with the U.S. Department of War on January 6, 2026.
The deal is designed to more than triple the annual production capacity of the PAC-3® Missile Segment Enhancement (MSE) interceptor, surging from current levels of approximately 600 units to a target of 2,000 units per year.
The agreement is a flagship outcome of the Department of War’s new Acquisition Transformation Strategy.
By providing long-term "demand certainty," the framework incentivizes Lockheed Martin and its massive global supply chain to invest in expanded tooling, facilities, and workforce.
To manage the financial burden of such a rapid scale-up, the deal utilizes a "collaborative financing model" that aims for cash neutrality in the early stages, allowing Lockheed to fund the expansion without immediate pressure on its balance sheet.
This "surging" of the "Arsenal of Freedom" follows a record-breaking 2025, where Lockheed Martin delivered 620 PAC-3 MSEs—a 20% year-over-year increase.
The PAC-3 MSE is a "hit-to-kill" interceptor, meaning it uses pure kinetic energy rather than a blast-fragmentation warhead to neutralize threats, making it the premier defense against advanced ballistic missiles, cruise missiles, and emerging hypersonic threats.
Profound Medical Corp. (NASDAQ:PROF) on Tuesday announced that Johns Hopkins Hospital has performed its first commercial prostate cancer treatment using the company's TULSA-PRO system, marking a key adoption milestone for the MRI-guided, incision-free ablation technology.
Bright Minds Biosciences (NASDAQ:DRUG) shares are under the spotlight following the announcement of "positive and significant" topline results from its Phase 2 BREAKTHROUGH study.
Alkermes (NASDAQ:ALKS) announced on January 6, 2026, that the U.S. FDA has granted Breakthrough Therapy Designation to alixorexton (formerly ALKS 2680) for the treatment of narcolepsy type 1 (NT1).
Apogee Therapeutics (NASDAQ:APGE) shares are trending today after the company reported positive interim Phase 1b results for zumilokibart (APG777), its half-life extended anti-IL-13 antibody.
Aclarion (NASDAQ:ACON) reached a significant clinical milestone on Tuesday, January 6, 2026, announcing the first patient enrollments at two prestigious new sites: Northwestern Medicine and Scripps Health.
This expansion brings the total number of active enrollment sites to four, with seven leading U.S. spine centers having completed full regulatory and operational setup.
AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.
